Thermo Fisher Scientific reports news across scientific instruments, laboratory equipment, diagnostics consumables, life science reagents and pharmaceutical services. Company updates commonly cover operating results, earnings calls, investor presentations and capital deployment through dividends, share repurchases and acquisitions.
Recurring developments also include collaborations tied to laboratory technologies, proteomics, biobank research, analytical instruments and biopharma customer services. Thermo Fisher’s brand portfolio includes Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD, and its completed Clario acquisition added endpoint data solutions for clinical trials to its Laboratory Products and Biopharma Services segment.
Thermo Fisher Scientific Inc. (NYSE: TMO), a leader in scientific services, announced that Marc N. Casper, chairman and CEO, will present at the Cowen Healthcare Conference on March 6, 2023, at 9:10 a.m. (EST). The presentation will be accessible via a webcast on the company's Investor section of its website. With annual revenue exceeding $40 billion, Thermo Fisher is committed to enhancing global health and safety through innovative technologies and services. For further details, visit www.thermofisher.com.
Thermo Fisher Scientific Inc. (NYSE: TMO) announced a quarterly cash dividend of $0.35 per common share, a 17% increase from the previous $0.30 dividend. This payment will be made on April 14, 2023, to stockholders recorded by March 15, 2023. The company, a leader in scientific services with annual revenues exceeding $40 billion, focuses on contributing to societal health and safety through innovative technologies and comprehensive laboratory services.
NATICK, Mass. - Mercy BioAnalytics announced that Dawn Mattoon, PhD, has taken over as Chief Executive Officer, transitioning from her previous role as Chief Operating Officer. Paul Blavin has moved to the position of Vice Chairman of the Board. Dr. Mattoon, who has been with the company for seven months, praised the team's progress in advancing their cancer detection technology. Her experience includes leadership roles in strategic initiatives at companies like Quanterix and Thermo Fisher Scientific. The company focuses on the early detection of cancers, particularly ovarian and lung cancers, through its Mercy Halo liquid biopsy platform.
Thermo Fisher Scientific (NYSE: TMO) announced a major step towards achieving its net-zero carbon emissions goal by 2050. The company signed a 20-year virtual power purchasing agreement with EDF Renewables to supply 545,000 MWh of renewable electricity annually from a new 200 MW solar project in Texas. By 2026, Thermo Fisher aims to power all U.S. operations entirely with renewable electricity. This initiative supports an increased target to cut Scope 1 and 2 greenhouse gas emissions by 50% from 2018 levels by 2030. The Millers Branch Solar project is set to be operational by December 2025, marking a significant shift toward sustainable practices.
Thermo Fisher Scientific Inc. (TMO) reported its Q4 and full-year 2022 results, showing a 7% increase in quarterly revenue to $11.45 billion and a 15% increase in annual revenue to $44.92 billion. The fourth quarter GAAP EPS was $4.01, down from $4.17 in 2021, while adjusted EPS was $5.40, compared to $6.54 previously. Notable achievements included the launch of innovative products and expansions in global capabilities. The company initiated 2023 guidance, expecting $45.3 billion in revenue and $23.70 in adjusted EPS.
Thermo Fisher Scientific Inc. (NYSE: TMO) will present at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023, at 10:30 a.m. (EST). CEO Marc N. Casper will lead the presentation, showcasing the company's commitment to advancing science globally. Thermo Fisher, with an annual revenue of approximately $40 billion, aims to make the world healthier, cleaner, and safer.
Investors can access the presentation via the Investors section of their website.
Thermo Fisher Scientific Inc. (NYSE: TMO) is set to release its financial results for Q4 and full year 2022 on February 1, 2023, before market opening. The company will also host a conference call at 8:30 a.m. EST to discuss its financial performance and future expectations. Thermo Fisher, with annual revenue around $40 billion, emphasizes its commitment to supporting life sciences and diagnostics. Interested parties can access the call and follow the details on the company’s website.
Thermo Fisher Scientific has completed its acquisition of The Binding Site Group for £2.3 billion ($2.8 billion). This acquisition expands Thermo Fisher's Specialty Diagnostics segment, enhancing its capabilities in oncology testing for multiple myeloma. The Binding Site's offerings are crucial for early diagnosis and monitoring of blood cancers, significantly improving patient outcomes. The transaction is expected to boost adjusted earnings per share by $0.07 in 2023. Thermo Fisher continues to lead in serving science with a projected annual revenue of around $40 billion.
Summary not available.
Thermo Fisher Scientific has announced the pricing of a €1.25 billion offering of euro-denominated senior notes. The offering includes €500 million of 3.200% senior notes due 2026 and €750 million of 3.650% senior notes due 2034. The expected closing date is on or about November 21, 2022. Proceeds from this offering will fund general corporate purposes, including acquisitions and debt refinancing. The company operates under an effective registration statement with the SEC, ensuring compliance and transparency for investors.